Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

548 indexed citations

Abstract

loading...

About

This paper, published in 2012, received 548 indexed citations. Written by Nathan M. Belliveau, Jens Huft, Paulo J.C. Lin, Sam Chen, Alex K. K. Leung, Ying K. Tam, Carl L. Hansen and Pieter R. Cullis covering the research area of Molecular Biology and Biomedical Engineering. It is primarily cited by scholars working on Molecular Biology (393 citations), Biomedical Engineering (174 citations) and Biomaterials (87 citations). Published in Molecular Therapy — Nucleic Acids.

Countries where authors are citing Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Specialization
Citations

This map shows the geographic impact of Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA more than expected).

Fields of papers citing Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1038/mtna.2012.28.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026